Live Breaking News & Updates on ப்ரைமரீ நோய் எதிர்ப்பு சக்தி பதில்

Stay updated with breaking news from ப்ரைமரீ நோய் எதிர்ப்பு சக்தி பதில். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

First Patient Enrolled in Biodesix and Addario Lung Cancer Medical Institute Study Aiming to Predict Patient Survival Using a Blood-based Biomarker

Share this article
Share this article
SAN CARLOS, Calif. and BOULDER, Colo., May 26, 2021 /PRNewswire/ Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, and Addario Lung Cancer Medical Institute (ALCMI) today announced they will present on the progress of Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy (BEACON-Lung). The BEACON-Lung study aims to evaluate biomarkers to predict overall survival and early progression outcomes in treatment-naïve advanced stage non-small cell lung cancer (NSCLC) patients with high PD-L1 expression. The first patient participant enrolled in the study this week. ....

Northwestern University , United States , Rush University Medical Center , Mary Jo Fidler , Meucci Villaflor , Raymondu Osarogiagbon , David Paul Carbone , Tony Addario , Maryj Fidler , James Jett , Amol Rao , Erin Marie Bertino , Bonniej Addario , Balazs Halmos , Addario Lung Cancer Medical Institute , Cell Therapy At Rush Medical College , Ohio State University Comprehensive Cancer Center , Baptist Cancer Center , Northwestern University Feinberg School Of Medicine , Roberth Lurie Comprehensive Cancer Center , Division Of Hematology , Department Of Internal Medicine , Albert Einstein College Of Medicine , Biodesix Inc , Montefiore Medical Center , Foundation For Lung Cancer ,

Biodesix to Showcase New Data on Patient Immune Profiling from Multiple Studies at World Lung Conference

Posted January 26th, 2021 for Biodesix

Important New Findings Validate Testing Strategies That Support Decision Making for Treatment of Patients with Non-Small Cell Lung Cancer (NSCLC)

BOULDER, CO, January 26, 2021 –Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that three abstracts from multiple clinical studies will be featured at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (WCLC), scheduled for January 28-31, 2021. Findings from these recent studies demonstrate that an individual patient’s immune profile can provide information to support treatment decisions for patients diagnosed with advanced non-small cell lung cancer (NSCLC). ....

United States , Kyung Hur , Scott Hutton , Young Kwang Chae , Wallace Akerley , Eric Schaefer , Highlands Oncology Group , Biodesix Inc , University Of Utah Huntsman Cancer Institute , Northwestern University Feinberg School Of Medicine , Non Small Cell Lung Cancer , International Association , Lung Cancer , World Conference , Utah Huntsman Cancer Institute , Immune Checkpoint Inhibition , Won Kyung Hur , Primary Immune Response , Northwestern University Feinberg School , Blood Based Host Immune Profile , Identify Aggressive Early Stage , Biodesix Lung Reflex , Nodify Lung , ஒன்றுபட்டது மாநிலங்களில் , கியுங் அவசரம் , ஸ்காட் ஹட்டன் ,